{"organizations": [], "uuid": "620969bd91b988f8ad4fb209373d9485d7f3df13", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/16", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/03/globe-newswire-fate-therapeutics-to-webcast-conference-call-reporting-first-quarter-2018-financial-results.html", "country": "US", "domain_rank": 767, "title": "Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-04T00:01:00.000+03:00", "replies_count": 0, "uuid": "620969bd91b988f8ad4fb209373d9485d7f3df13"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/03/globe-newswire-fate-therapeutics-to-webcast-conference-call-reporting-first-quarter-2018-financial-results.html", "ord_in_thread": 0, "title": "Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results", "locations": [], "entities": {"persons": [], "locations": [{"name": "san diego", "sentiment": "none"}], "organizations": [{"name": "company", "sentiment": "none"}, {"name": "about fate therapeutics, inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN DIEGO, Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live audio webcast on Thursday, May 10, 2018 at 5:00 p.m. ET to report its first quarter 2018 financial results and provide a corporate update.\nIn order to participate in the conference call, please dial 877-303-6235 (domestic) or 631-291-4837 (international) and refer to conference ID 5592629. The live webcast can be accessed under \"Events & Presentations\" in the Investors and Media section of the Company's website at www.fatetherapeutics.com . The archived webcast will be available on the Company's website beginning approximately two hours after the event.\nAbout Fate Therapeutics, Inc.\nFate Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Fate Therapeutics is headquartered in San Diego, CA.\nContact:\nChristina Tartaglia\nStern Investor Relations, Inc.\n212.362.1200\nchristina@sternir.com\nSource:Fate Therapeutics, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e"], "published": "2018-05-04T00:01:00.000+03:00", "crawled": "2018-05-04T02:49:21.015+03:00", "highlightTitle": ""}